Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
$21.80
+0.9%
$22.50
$20.02
$30.46
$12.07B0.81827,491 shs674,484 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$95.14
+0.2%
$89.30
$36.36
$120.74
$12.59B1.481.96 million shs1.77 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$50.14
+2.0%
$51.85
$23.30
$66.06
$3.06B2.221.48 million shs2.58 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$38.90
+1.1%
$33.87
$22.61
$50.71
$3.07B1.89964,791 shs944,926 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
0.00%-1.84%-7.73%-11.54%-24.83%
Guardant Health, Inc. stock logo
GH
Guardant Health
0.00%-0.82%+5.05%-9.47%+133.39%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-13.51%-17.79%+0.12%+58.97%
Veracyte, Inc. stock logo
VCYT
Veracyte
0.00%-4.80%+13.85%+7.58%+31.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
$21.80
+0.9%
$22.50
$20.02
$30.46
$12.07B0.81827,491 shs674,484 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$95.14
+0.2%
$89.30
$36.36
$120.74
$12.59B1.481.96 million shs1.77 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$50.14
+2.0%
$51.85
$23.30
$66.06
$3.06B2.221.48 million shs2.58 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$38.90
+1.1%
$33.87
$22.61
$50.71
$3.07B1.89964,791 shs944,926 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
0.00%-1.84%-7.73%-11.54%-24.83%
Guardant Health, Inc. stock logo
GH
Guardant Health
0.00%-0.82%+5.05%-9.47%+133.39%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-13.51%-17.79%+0.12%+58.97%
Veracyte, Inc. stock logo
VCYT
Veracyte
0.00%-4.80%+13.85%+7.58%+31.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.56
Reduce$28.0028.47% Upside
Guardant Health, Inc. stock logo
GH
Guardant Health
2.86
Moderate Buy$129.4236.04% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.5712.83% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.38
Hold$44.8315.25% Upside

Current Analyst Ratings Breakdown

Latest VCYT, TWST, GH, and FMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
Guardant Health, Inc. stock logo
GH
Guardant Health
Reiterated RatingOverweight$135.00
5/8/2026
Guardant Health, Inc. stock logo
GH
Guardant Health
Boost Price TargetOverweight$115.00 ➝ $120.00
5/8/2026
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
UpgradeStrong SellModerate Sell
5/8/2026
Guardant Health, Inc. stock logo
GH
Guardant Health
Boost Price TargetOverweight$130.00 ➝ $135.00
5/7/2026
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
DowngradeHold (C+)Hold (C)
5/6/2026
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
Reiterated RatingUnderweight
5/6/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Boost Price TargetBuy$48.00 ➝ $52.00
5/6/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Boost Price TargetHold$40.00 ➝ $42.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
$22.20B0.55$5.62 per share3.88$28.93 per share0.75
Guardant Health, Inc. stock logo
GH
Guardant Health
$982.02M12.85N/AN/A($0.79) per share-120.42
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M8.29N/AN/A$7.84 per share6.40
Veracyte, Inc. stock logo
VCYT
Veracyte
$517.15M6.00$1.51 per share25.83$16.57 per share2.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
$1.11B$1.9011.388.973.904.88%8.90%4.05%8/4/2026 (Estimated)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$416.28M-$3.39N/AN/AN/A-40.10%N/A-26.42%7/29/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.0935.3027.39N/A16.25%9.07%8.38%8/5/2026 (Estimated)

Latest VCYT, TWST, GH, and FMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
$0.59$0.53-$0.06$0.25$5.41 billion$5.34 billion
5/5/2026Q1 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.34$0.52+$0.18$0.35$130.36 million$139.07 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
3/31/2026Q1 2026
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
N/A$1.0530N/A$0.25N/A$5.34 billion
2/25/2026Q4 2025
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.41$0.53+$0.12$0.51$135.79 million$140.64 million
2/24/2026Q4 2025 (Media)
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
$0.67$0.83+$0.16$0.67$4.80 billion$5.95 billion
2/19/2026Q4 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.43-$0.50-$0.07-$1.00$269.74 million$281.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
$0.572.62%+2.66%30.00%N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A

Latest VCYT, TWST, GH, and FMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2026
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
annual$0.87163.85%5/22/20265/22/20266/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
0.40
1.20
0.86
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
4.68
4.39
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.31
8.92

Institutional Ownership

CompanyInstitutional Ownership
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
8.37%
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
5.60%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresenius Medical Care AG & Co. KGaA stock logo
FMS
Fresenius Medical Care AG & Co. KGaA
1,488558.58 millionN/AOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
2,506132.60 million125.17 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79079.79 million78.68 millionOptionable

Recent News About These Companies

Veracyte Inc Earnings Call Signals Profitable Growth
Veracyte: Q1 Earnings Snapshot
Veracyte (VCYT) Q1 2026 Earnings Transcript
Veracyte Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Fresenius Medical Care AG & Co. KGaA stock logo

Fresenius Medical Care AG & Co. KGaA NYSE:FMS

$21.80 +0.20 (+0.90%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$95.14 +0.22 (+0.23%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$50.14 +0.97 (+1.97%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$38.90 +0.42 (+1.09%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.